Non-Hodgkin lymphoma: Retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 6, 2008, Pages 1074-1080

  Moulin Romsee, G ^a   Spaepen, K ^a   Stroobants, S ^a   Mortelmans, L ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Costs; Lymphoma; PET; Response assessment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HOSPITALIZATION; HUMAN; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EUROPE; FEMALE; FLUORODEOXYGLUCOSE F18; HEALTH CARE COSTS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PREDNISONE; RADIOPHARMACEUTICALS; VINCRISTINE;

EID: 43749104621     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0690-0     Document Type: Article

References (19)

1. Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using F-FDG PET. J Nucl Med. 2002;43(8):1028-30.
2. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer. 2002;38:1167-72.
3. Doorduijn JK, Buijt I, van der Holt B, van Agthoven M, Sonneveld P, Uyl-de Groot CA. Economic evaluation of prophylactic granulocyte colony-stimulating factor during chemotherapy in elderly patients with aggressive NHL. Haematologica. 2004;89:1109-17.
4. Coleman M, Kostakoglu L. Early 18F-labled fluoro-2-deoxy-D-glucose positron emission tomography scanning in lymphoma. Cancer. 2006;107(7):1425-8.
5. Spaepen K, Mortelmans L. Evaluation of treatment response in patients with lymphoma using F-FDG-PET: differences between NHL and HD QJ. Nucl Med. 2001;45:269-73.
6. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of PET with F-FDG after first line chemotherapy in NHL: is FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19(2):414-9.
7. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body PET using FDG for post treatment evaluation in HD and NHL has a higher diagnostic and prognostic value than classical CT imaging. Blood. 1999;94(2):429-33.
8. Schmitz S, Aly F, Steinmetz T, Diehl V, Rehwald U. Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma. Onkologie. 2006;29:258-64.
9. Kuruvilla J, Cavalcanti R, Keating A, Crump M. Addition of Rituximab to CHOP is an attractive strategy as primary therapy for DLBCL in patients less 60 y: an economic analysis. Blood 2004;104:Abstract 3126.
10. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance Rituximab in older patients with DLBCL. J Clin Oncol. 2006;24(19):3121-7.
11. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of Rituximab in DLBCL in the Netherlands. Eur J Haematol. 2005;74:194-202.
12. van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA. Cost determinants in aggressive NHL. Haematologica. 2005;90:661-71.
13. Cvetkovic RS, Fabry U, Wildberger JE, Zimmy M, Reinartz P, Nowak B, et al. Spotlight on Rituximab in NHL and chronic lymphotic leukemia. Biodrugs. 2006;20(4):253-7.
14. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging PET with F-FDG predicts outcome in patients with aggressive NHL. Ann Oncol. 2002;13:1356-63.
15. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. FDG-PET as a prognostic indicator in the treatment of aggressive NHL-comparison with CT. Leuk Lymphoma. 2000;39(5-6):543-53.
16. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-27.
17. Römer W, Hanauske AR, Ziegler S, Thödtmann R, Weber W, Fuchs C, et al. PET in NHL: assessment of chemotherapy with FDG. Blood. 1998;91(12):4464-71.
18. Cremerius U, Fabry U, Wildberger JE, Zimmy M, Reinartz P, Nowak B, et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro- deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapyand autologous stem cell transplantation for non-hodgkin's lymphoma. Bone Marrow Transplant. 2002;30:103-11.
19. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102(11):53-9.